thiourea and Duodenal-Diseases

thiourea has been researched along with Duodenal-Diseases* in 3 studies

Trials

2 trial(s) available for thiourea and Duodenal-Diseases

Article	Year
Nocturnal metiamide treatment in the management of healed duodenal ulceration. Gut, 1977, Volume: 18, Issue:6 This paper presents the results of a pilot study to investigate whether the administration of a nocturnal dose of metiamide (the first orally active H2 receptor antagonist) would prevent or delay the relapse of duodenal ulceration after initial ulcer healing. Sixteen patients took part in a double-blind trial to compare metiamide (400 mg) with placebo. Endoscopically confirmed duodenal ulcer relapses occurred in two out of eight on metiamide and six out of eight on placebo. There was a significant prolongation of remission in those in those on the active drug with an apparent reduction in duodenitis. Topics: Adult; Aged; Clinical Trials as Topic; Duodenal Diseases; Duodenal Ulcer; Enteritis; Humans; Metiamide; Middle Aged; Recurrence; Remission, Spontaneous; Thiourea; Time Factors	1977
Treatment of duodenal ulcer by metiamide. A multicentre trial. Lancet (London, England), 1975, Oct-25, Volume: 2, Issue:7939 In a multicentre double-blind trial 68 patients with endoscopically confirmed duodenal ulceration received metiamide (36 patients) or placebo (32 patients) for four weeks. Healing of duodenal ulcers was significantly increased in patients receiving metiamide (67%) compared with those on placebo (25%). There was also an assoicated significant decrease in daytime pain and antacid consumption in those on metiamide. Topics: Antacids; Clinical Trials as Topic; Drug Evaluation; Duodenal Diseases; Duodenal Ulcer; Enteritis; Humans; Metiamide; Pain; Thiourea	1975

Article

Year

Nocturnal metiamide treatment in the management of healed duodenal ulceration.

Gut, 1977, Volume: 18, Issue:6

This paper presents the results of a pilot study to investigate whether the administration of a nocturnal dose of metiamide (the first orally active H2 receptor antagonist) would prevent or delay the relapse of duodenal ulceration after initial ulcer healing. Sixteen patients took part in a double-blind trial to compare metiamide (400 mg) with placebo. Endoscopically confirmed duodenal ulcer relapses occurred in two out of eight on metiamide and six out of eight on placebo. There was a significant prolongation of remission in those in those on the active drug with an apparent reduction in duodenitis.

Topics: Adult; Aged; Clinical Trials as Topic; Duodenal Diseases; Duodenal Ulcer; Enteritis; Humans; Metiamide; Middle Aged; Recurrence; Remission, Spontaneous; Thiourea; Time Factors

1977

Treatment of duodenal ulcer by metiamide. A multicentre trial.

Lancet (London, England), 1975, Oct-25, Volume: 2, Issue:7939

In a multicentre double-blind trial 68 patients with endoscopically confirmed duodenal ulceration received metiamide (36 patients) or placebo (32 patients) for four weeks. Healing of duodenal ulcers was significantly increased in patients receiving metiamide (67%) compared with those on placebo (25%). There was also an assoicated significant decrease in daytime pain and antacid consumption in those on metiamide.

Topics: Antacids; Clinical Trials as Topic; Drug Evaluation; Duodenal Diseases; Duodenal Ulcer; Enteritis; Humans; Metiamide; Pain; Thiourea

1975

Other Studies

1 other study(ies) available for thiourea and Duodenal-Diseases

Article	Year
[Pharmacologic-endocrinological findings in animal experiments with TURISYNCHRON and SUISYNCHROM. 2. Toxicologic findings]. Archiv fur experimentelle Veterinarmedizin, 1974, Volume: 28, Issue:5 Acute, subacute and chronic toxicity of TURISYNCHRON and its zinc complex (SUISYNCHRON) was tested in mice, rats and dogs. The acute toxicity of SUISYNCHRON was lower than that of TURISYNCHRON in mice and rats. Ulcerative lesions in the duodenum produced by high doses of SUISYNCHRON were quantitatively less pronounced than those produced by similar doses of TURISYNCHRON. Subacute toxicity testing in rats showed that neither preparation had any toxic effect on haematological, clinical chemical or histological criteria in the dosages selected. Chronic toxicity testing of TURISYNCHRON in dogs did not reveal any evidence of toxic damage. Topics: Acute Disease; Administration, Oral; Animals; Atropine; Body Weight; Chlorpromazine; Chronic Disease; Duodenal Diseases; Female; Injections, Subcutaneous; Lethal Dose 50; Maternal-Fetal Exchange; Methallibure; Mice; Organ Size; Papaverine; Peptic Ulcer; Poisoning; Pregnancy; Rats; Sex Factors; Structure-Activity Relationship; Thiourea; Zinc	1974

Article

Year

[Pharmacologic-endocrinological findings in animal experiments with TURISYNCHRON and SUISYNCHROM. 2. Toxicologic findings].

Archiv fur experimentelle Veterinarmedizin, 1974, Volume: 28, Issue:5

Acute, subacute and chronic toxicity of TURISYNCHRON and its zinc complex (SUISYNCHRON) was tested in mice, rats and dogs. The acute toxicity of SUISYNCHRON was lower than that of TURISYNCHRON in mice and rats. Ulcerative lesions in the duodenum produced by high doses of SUISYNCHRON were quantitatively less pronounced than those produced by similar doses of TURISYNCHRON. Subacute toxicity testing in rats showed that neither preparation had any toxic effect on haematological, clinical chemical or histological criteria in the dosages selected. Chronic toxicity testing of TURISYNCHRON in dogs did not reveal any evidence of toxic damage.

Topics: Acute Disease; Administration, Oral; Animals; Atropine; Body Weight; Chlorpromazine; Chronic Disease; Duodenal Diseases; Female; Injections, Subcutaneous; Lethal Dose 50; Maternal-Fetal Exchange; Methallibure; Mice; Organ Size; Papaverine; Peptic Ulcer; Poisoning; Pregnancy; Rats; Sex Factors; Structure-Activity Relationship; Thiourea; Zinc

1974